Primary breast angiosarcoma: avoiding a common trap.

Case Rep Oncol Med

Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHA Universitaire de Québec, 1050 chemin Sainte-Foy, Québec City, QC, Canada G1S 4L8.

Published: August 2012

Background. Primary breast angiosarcoma is a rare entity. Case. Initial diagnosis was a benign hemangioma at core biopsy. Wide local excision was performed, with positive margins. Pathology after surgery reported a moderately differentiated angiosarcoma. Tumor was finally treated using mastectomy and radiations. She developed a second angiosarcoma in contralateral breast, with an initial diagnosis on core biopsy of an atypical vascular lesion and was again treated using mastectomy and radiations. She developed bones and lung metastases. Conclusion. Primary breast angiosarcoma is a rare entity often difficult to diagnose on core biopsy, and a benign differential diagnosis is frequent. A highly vascular breast mass should always be considered malignant until proven otherwise. Surgical treatment seems to be the best course of action. There is a lack of data proving efficacy of adjuvant chemotherapy and radiation therapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3350177PMC
http://dx.doi.org/10.1155/2011/517047DOI Listing

Publication Analysis

Top Keywords

primary breast
12
breast angiosarcoma
12
core biopsy
12
angiosarcoma rare
8
rare entity
8
initial diagnosis
8
treated mastectomy
8
mastectomy radiations
8
radiations developed
8
angiosarcoma
5

Similar Publications

Background: Several approaches are being explored for engineering off-the-shelf chimeric antigen receptor (CAR) T cells. In this study, we engineered chimeric Fcγ receptor (FcγR) T cells and tested their potential as a versatile platform for universal T cell therapy.

Methods: Chimeric FcγR (CFR) constructs were generated using three distinct forms of FcγR, namely CD16A, CD32A, and CD64.

View Article and Find Full Text PDF

Purpose: The purpose of this study was to evaluate the feasibility and safety of indocyanine green (ICG) fluorescence as an alternative to traditional sentinel lymph node biopsy (SLNB) techniques in breast cancer (BC) patients undergoing neoadjuvant chemotherapy (NAC). Specifically, the study aimed to assess sentinel node identification rates and the effectiveness of ICG in axillary staging without the use of radioactive tracers.

Methods: This retrospective study included 71 BC patients treated with NAC, who underwent SLNB using ICG fluorescence between 2020 and 2024.

View Article and Find Full Text PDF

Objectives: Sedentary behaviour (SB) is associated with increased risks of breast, colorectal, endometrial, ovarian and rectal cancers. However, the number of cancer cases attributable to SB in Germany and the associated costs are unknown.

Setting: Numbers and proportions (population-attributable fractions, PAF) of new cancer cases attributable to SB with published risk estimates for Germany for the years 2024, 2030 and 2040.

View Article and Find Full Text PDF

The impact of exercise during radiotherapy on treatment-related side effects in breast cancer patients: A systematic review and meta-analysis.

Int J Nurs Stud

December 2024

Department of Rehabilitation, School of Nursing, Jilin University, 965 Xinjiang Street, Chaoyang District, Changchun 130021, PR China. Electronic address:

Purpose: Radiation therapy for breast cancer often causes side effects like cancer-related fatigue, depression, and sleep disorders, impacting health-related quality of life, psychosocial aspects, and physical function. Exercise therapy is commonly used to manage cancer-related fatigue, but its effectiveness remains uncertain due to varying patient conditions and adherence. This systematic review aims to assess exercise interventions during radiotherapy for their effects on physiological and psychological side effects in breast cancer patients, clarifying efficacy and exploring different intervention types.

View Article and Find Full Text PDF

Retrospective comparative survival analysis of ablation plus systemic therapy versus systemic therapy alone for breast cancer liver metastases, stratified by extrahepatic metastases status.

Breast

January 2025

Department of Minimally Invasive Interventional Therapy, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR China. Electronic address:

Background: Current decision-making for the treatment of breast cancer liver metastases (BCLM) using ablation lacks strong evidence, especially for patients combined with extrahepatic metastases.

Purpose: To assess whether ablation plus systemic therapy (AS) improves survival outcomes in patients with BCLM compared to systemic therapy alone.

Materials And Methods: This retrospective study analyzed patients with BCLM who received either AS or systemic therapy alone.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!